MSN Anti-Cancer Nanomedicines: Chemotherapy Enhancement, Overcoming of Drug Resistance, and Metastasis Inhibition
MSN Anti-Cancer Nanomedicines: Chemotherapy Enhancement, Overcoming of Drug Resistance, and Metastasis Inhibition
复制标题
MSN抗癌纳米药物：增强化疗、克服耐药性、抑制转移
DOI：
10.1002/adma.201303123
复制
发表时间：
2014-01-01
影响因子：
29.4
通讯作者：
Shi, Jianlin
中科院分区：
文献类型：
--
作者：
He, Qianjun;Shi, Jianlin
在抗癌战争中，导致癌症高死亡率和复发率的主要障碍有三个：由于缺乏肿瘤选择性，抗癌药物对正常组织产生严重的毒副作用；对游离化疗药物的多药耐药性（MDR）；癌细胞的致命转移。基于介孔二氧化硅纳米粒子（MSNs）的先进纳米药物的开发有望克服上述三个主要障碍。鉴于抗癌策略的快速发展，本综述重点介绍了MSN抗癌纳米药物在提高化疗疗效、克服多药耐药性和抑制转移方面的最新进展。此外，我们对基于MSNs的抗癌纳米药物的未来发展进行了展望，并提出了几种创新且具有前瞻性的抗癌策略，包括肿瘤组织 - 细胞 - 细胞核连续靶向给药策略、肿瘤细胞选择性核靶向给药策略、多靶向和多药策略，以及借助功能化的中空/核 - 壳结构MSNs进行的化学/放射/光动力/超声/热联合多模式治疗。
In the anti-cancer war, there are three main obstacles resulting in high mortality and recurrence rate of cancers: the severe toxic side effect of anti-cancer drugs to normal tissues due to the lack of tumor-selectivity, the multi-drug resistance (MDR) to free chemotherapeutic drugs and the deadly metastases of cancer cells. The development of state-of-art nanomedicines based on mesoporous silica nanoparticles (MSNs) is expected to overcome the above three main obstacles. In the view of the fast development of anti-cancer strategy, this review highlights the most recent advances of MSN anti-cancer nanomedicines in enhancing chemotherapeutic efficacy, overcoming the MDR and inhibiting metastasis. Furthermore, we give an outlook of the future development of MSNs-based anti-cancer nanomedicines, and propose several innovative and forward-looking anti-cancer strategies, including tumor tissue-cell-nuclear successionally targeted drug delivery strategy, tumor cell-selective nuclear-targeted drug delivery strategy, multi-targeting and multi-drug strategy, chemo-/radio-/photodynamic-/ultrasound-/thermo-combined multi-modal therapy by virtue of functionalized hollow/rattle-structured MSNs.